Crinetics Pharmaceuticals, Inc.
CRNX
$35.20
$0.732.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -34.11% | -33.71% | -45.27% | -45.52% | -33.58% |
| Total Depreciation and Amortization | 200.76% | 182.05% | 168.93% | 67.49% | -6.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.60% | 39.98% | 73.43% | 92.01% | 82.44% |
| Change in Net Operating Assets | -103.71% | -144.33% | 357.75% | 491.85% | 250.55% |
| Cash from Operations | -67.92% | -51.97% | 0.26% | -29.81% | -9.40% |
| Capital Expenditure | -10.05% | 84.91% | -302.95% | -8,225.00% | -241.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -526.42% | 111.13% | -266.34% | -96.64% | -332.64% |
| Cash from Investing | -520.89% | 110.66% | -270.64% | -99.37% | -336.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,408.44% | -83.63% | -57.86% | 84,483.47% | 53,132.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,337.65% | 92.99% | 104.00% | -- | -2,326.19% |
| Cash from Financing | 1,360.88% | -83.03% | -56.58% | 81,216.94% | 32,878.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 40.02% | -85.37% | -5,613.71% | 3,902.19% | -5,091.37% |
